The pivotal ANDROMEDA-SHOCK study (2019) demonstrated a decreased mortality rate of eight percentage points among patients with septic shock whose treatment involved a resuscitation strategy targeting capillary refill time (CRT) normalization, compared with a strategy focused on blood lactate levels. Subsequently, the Surviving Sepsis Campaign added CRT monitoring as part of standard practice for treating sepsis.  

This study and the update to clinical guidance directly reinforce the value of the ProMedix FlowSense CRT detector that Matthew Hansen MD, MCR and David Sheridan MD, MCR envisioned in 2015. Drs. Hansen and Sheridan’s pursuit of an accurate, digital measure of capillary refill time, designed to assist in the diagnosis and treatment of diseases ranging from sepsis to dehydration, was developed in concert with Dr. Baker and Welch Allyn. The team filed their first patent in 2016; their first research paper was published the following year. Subsequent development enabled them to refine their discovery, leading to the FlowSense CRT detector, which currently supports multiple patient studies.  

The problem with CRT monitoring lies in the enormous variability between different provider’s measurements and even between different trials by the same clinician.  

The next evolution: ProMedix FlowSense CRT Sensor  

The FlowSense CRT sensor standardizes CRT monitoring and obtains accurate, consistent results. Building on the ANDROMEDA-SHOCK study, ProMedix has launched a prospective, observational study in the ER to determine the ability of the device to further improve early sepsis detection and increase sepsis survival rates.